Stockscreener 앱 받기
4.30
8.59%
0.34
시간 외 거래:
4.25
-0.05
-1.16%
전일 마감가:
$3.96
열려 있는:
$4.01
하루 거래량:
684.47K
Relative Volume:
0.60
시가총액:
$154.74M
수익:
$317.00K
순이익/손실:
$-53.47M
주가수익비율:
-2.2751
EPS:
-1.89
순현금흐름:
$-49.31M
1주 성능:
-0.69%
1개월 성능:
+136.26%
6개월 성능:
+112.87%
1년 성능:
+267.52%
1일 변동 폭
$3.95
$4.32
1주일 범위
$3.82
$4.55
52주 변동 폭
$1.00
$4.60
Immuneering Corp Stock (IMRX) Company Profile
명칭
Immuneering Corp
전화
617-500-8080
주소
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
IMRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
4.30 | 155.82M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-13 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-03-15 | 재확인 | Needham | Buy |
| 2024-03-15 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | 개시 | Needham | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-04-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-04-19 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | 개시 | Mizuho | Neutral |
| 2023-02-03 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | 개시 | Chardan Capital Markets | Buy |
| 2022-04-01 | 개시 | Oppenheimer | Outperform |
| 2022-01-07 | 개시 | Piper Sandler | Overweight |
모두보기
Immuneering Corp 주식(IMRX)의 최신 뉴스
What makes Immuneering Corporation stock price move sharplyTop Gaining Low Risk Assets - Newser
Why Immuneering Corporation stock attracts strong analyst attentionShort Term Profit Focus - Newser
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - Quantisnow
Revolutionary Cancer Drug Gets Patent Protection Until 2042: Clinical Data Shows 94% Survival vs 67% Standard Care - Stock Titan
Immuneering director Hausman buys IMRX stock worth $19,862 By Investing.com - Investing.com South Africa
Immuneering (IMRX) chief people officer Neufeld buys $2498 in stock By Investing.com - Investing.com South Africa
Immuneering director Hausman buys IMRX stock worth $19,862 - Investing.com
Immuneering (IMRX) chief people officer Neufeld buys $2498 in stock - Investing.com
Insider Buying: Thomas Schall Acquires Additional Shares of Immu - GuruFocus
At $3.02 Price, Immuneering Corp (IMRX) Is Sitting And Waiting - Stocksregister
Immuneering Corporation (NASDAQ:IMRX) Receives $13.25 Consensus PT from Brokerages - Defense World
Immuneering (IMRX) CEO Zeskind buys $50k+ in shares - Investing.com
Immuneering (NASDAQ:IMRX) Receives Buy Rating from Needham & Company LLC - Defense World
Immuneering (IMRX) Target Price Raised by Mizuho Analyst | IMRX Stock News - GuruFocus
Chardan Capital Maintains Buy Rating on IMRX with $13 Price Targ - GuruFocus
Metric Deep Dive: Understanding La Rosa Holdings Corp (LRHC) Through its Ratios - DWinneX
Financial Analysis: TNL Mediagene (TNMG)’s Ratios Unveil Key Insights - DWinneX
Immuneering (IMRX) Price Target Raised by Mizuho Following Positive Trial Data | IMRX Stock News - GuruFocus
Immuneering stock price target raised to $10 at Mizuho on cancer drug data - Investing.com
Immuneering's Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - MENAFN.com
Immuneering’s Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - Asianet Newsable
Immuneering’s atebimetinibin shows positive survival data in pancreatic cancer - TipRanks
Immuneering stock rises after positive pancreatic cancer trial data - Investing.com
Immuneering (IMRX) Reports Promising Phase 2a Trial Results for Pancreatic Cancer Treatment | IMRX Stock News - GuruFocus
Pancreatic Cancer Breakthrough: New Drug Shows 94% Survival Rate vs 67% Standard Care in Phase 2a Trial - Stock Titan
Immuneering Reports Positive Overall Survival Data For Atebimetinib (Imm-1-104) From Phase 2A Trial In Pancreatic Cancer Patients - MarketScreener
Immuneering Corp holds annual stockholder meeting By Investing.com - Investing.com Canada
Immuneering Corp holds annual stockholder meeting - Investing.com Australia
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - The Manila Times
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - GlobeNewswire Inc.
Two Sigma Investments LP Purchases 10,126 Shares of Immuneering Co. (NASDAQ:IMRX) - Defense World
Immuneering Co. (NASDAQ:IMRX) Stock Position Reduced by Millennium Management LLC - Defense World
Immuneering’s (IMRX) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
Needham Maintains Buy Rating on IMRX with Price Target of $9.00 - GuruFocus
Full Immuneering Leadership Team Reveals Latest Pipeline Updates at Prestigious Jefferies Conference - Stock Titan
‘Take the Plunge,’ Says Top Investor About Intel Stock - The Globe and Mail
Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.0 - GuruFocus
Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst - GuruFocus
Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst | IMRX Stock News - GuruFocus
21,432 Shares in Immuneering Co. (NASDAQ:IMRX) Acquired by Marshall Wace LLP - Defense World
Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.00 | IMRX Stock News - GuruFocus
Immuneering Corp. Reports Promising Q1 2025 Results - TipRanks
Immuneering (IMRX) Stock Rating and Price Target Update | IMRX S - GuruFocus
Immuneering reports Q1 EPS (42c), consensus (58c) - TipRanks
Immuneering Corp SEC 10-Q Report - TradingView
Immuneering Reports Breakthrough: Cancer Drug Achieves 13-Month Survival in Late-Stage Pancreatic Cancer Patient - Stock Titan
IMRXImmuneering Corp Latest Stock News & Market Updates - Stock Titan
Charting the Course: Immuneering Corp’s IMRX Stock Prospects - investchronicle.com
What technical indicators reveal about IMRX stock - uspostnews.com
Immuneering Co. (NASDAQ:IMRX) Short Interest Update - Defense World
Immuneering Co. (NASDAQ:IMRX) Shares Bought by HighTower Advisors LLC - Defense World
Immuneering Corp (IMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.64%
0.37%
자본화:
|
볼륨(24시간):